Fineline Cube

Follow:
14467 Articles
MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability
Medical Device

MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability

CompanyDrug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer

CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion
CompanyDrug

CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion

Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
CompanyDrug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

European Commission Approves Bristol Myers Squibb's Sotyktu for Psoriatic Arthritis Following FDA Clearance
CompanyDrug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
CompanyDeals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

CompanyDrug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis

Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
CompanyDrug

Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer

Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance
Company

Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

CompanyDrug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda